Antimicrobials News

Infectious Disease News attended the World Anti-Microbial Resistance Congress in Washington, D.C., and asked Cornelius (Neil) J. Clancy, MD, associate professor of medicine and director of the extensively drug-resistant pathogen lab and mycology program at the University of Pittsburgh, what he saw and heard during the meeting.

Dissemination and implementation science is underutilized in the field of infectious diseases despite its demonstrated positive impact on clinical practice in other specialties, according to researchers, who described reasons and recommendations for its use.

WASHINGTON — Entasis Therapeutics announced at the World Anti-Microbial Resistance Congress that it has enrolled the first patient in a global phase 3 trial of oral zoliflodacin for the treatment of uncomplicated gonorrhea.

WASHINGTON — Candida auris is a “ticking time bomb” — an aggressive and naturally resistant pathogen with few options for treatment, an expert said here, highlighting the need for more funding and research to address the threat of fungal pathogens.

WASHINGTON — In this video from the World Anti-Microbial Resistance Congress, Debra A. Goff, PharmD, FIDSA, an infectious diseases specialist at The Ohio State University College of Pharmacy, discusses the reasons why hospitals are slow to use new antibiotics.

Prospective audit and feedback is a staple intervention used by antimicrobial stewardship programs, or ASPs, to reduce antimicrobial use and improve patient outcomes. The intensity of the approach can vary.

In this video from the World Anti-Microbial Resistance Congress, Kerry LaPlante, PharmD, FCCP, FIDSA, a professor of pharmacy at the University of Rhode Island College of Pharmacy, discusses the pharmacist’s role in antibiotic stewardship.

A 2-day course of prophylactic antibiotic therapy lowered the incidence of early ventilator-associated pneumonia among patients treated with target temperature management after out-of-hospital cardiac arrest, according to results from the ANTHARTIC trial.

The fifth annual World Anti-Microbial Resistance Congress — to be held in Washington, D.C., from Nov. 7 to 8 — will address antibiotic research and development, diagnostics, antimicrobial stewardship and innovation.

The FDA approved Talicia for the treatment of Helicobacter pylori infection in adults, manufacturer Redhill Biopharma announced.